Study to Evaluate CD8 PET Imaging as a Marker of Immune Response to Stereotactic Body Radiation Therapy (ELIXR)

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 20, 2022

Primary Completion Date

October 5, 2026

Study Completion Date

October 5, 2026

Conditions

Metastatic Malignant Solid NeoplasmLymphoma

Interventions

PROCEDURE

Positron Emission Tomography

Undergo PET

RADIATION

Stereotactic Body Radiation Therapy

Undergo SBRT

DRUG

Zirconium Zr 89-Df-Crefmirlimab

Given IV

RADIATION

Intensity Modulated Radiation Therapy

IMRT for Lymphoma patients only

Trial Locations (1)

RECRUITING

City of Hope Medical Center, Duarte

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER